Literature DB >> 10886251

Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury.

M Dantas1, R S Costa, J E Barbosa, M S Graeff, W Sarti, I F De Carvalho.   

Abstract

Administration of rabbit anti-rat lung serum (PNTS) to rats produces a fulminant haemorrhagic pneumonitis sensitive to the availability of complement. The present experiments were undertaken to assess whether a high dose of IVIG can affect the development of this kind of cytotoxic reaction. The experimental design included groups of Wistar rats pretreated intravenously with physiologic saline, IVIG or a preparation of human F(ab')2 fragments. One hour later the animals were challenged with either saline or PNTS. At 30 min after challenge, blood was collected and the lungs were removed. Pulmonary damage was evaluated by light microscopy; C3 deposits and the binding of immunoglobulins to the alveolar septa were assayed by immunofluorescence. The serum complement activity of the classical and alternative pathways was estimated by a kinetic technique. Pretreatment with IVIG decreased binding of rabbit anti-lung antibodies to alveolar septa and prevented the deposition of C3. These results indicate that pretreatment with IVIG inhibits the binding of the pathogenic antibody to lung tissue. Human IgG binding was not detected in any animal. The protection against lung injury afforded by pretreatment with IVIG, in contrast to the pneumotoxic effect of PNTS observed in control animals, was evident despite the administration of F(ab')2 to the rats. Since pretreatment with F(ab')2 failed to prevent the acute lung lesion, our results indicate that the attenuation afforded by IVIG in this model of complement-dependent tissue injury seems to be related to the integrity of the IgG molecule.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886251      PMCID: PMC1905663          DOI: 10.1046/j.1365-2249.2000.01252.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Forssman antigen in the guinea pig: a histologic study.

Authors:  G S SPEAR
Journal:  Bull Johns Hopkins Hosp       Date:  1962-11

2.  Prevention of acute immunological lung lesion in rats by decomplementing treatment.

Authors:  I F de Carvalho; H L de Oliveira; J A Laus-Filho; W Sarti
Journal:  Immunology       Date:  1969-05       Impact factor: 7.397

3.  Complement and heterophile shock.

Authors:  G S Spear; I Kihara
Journal:  Johns Hopkins Med J       Date:  1970-04

4.  Immunopathologic studies of an experimental model resembling Goodpasture's syndrome.

Authors:  J E Hagadorn; J J Vazquez; T R Kinney
Journal:  Am J Pathol       Date:  1969-10       Impact factor: 4.307

5.  Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses.

Authors:  R B Polhill; K M Pruitt; R B Johnston
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

6.  Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity.

Authors:  M Berger; P Rosenkranz; C Y Brown
Journal:  Clin Immunol Immunopathol       Date:  1985-02

7.  Experimental hemorrhagic pneumonitis produced by heterologous anti-lung antibody.

Authors:  W F Willoughby; F J Dixon
Journal:  J Immunol       Date:  1970-01       Impact factor: 5.422

8.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

9.  Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat.

Authors:  W M Bagchus; P J Hoedemaeker; J Rozing; W W Bakker
Journal:  Lab Invest       Date:  1986-12       Impact factor: 5.662

10.  The interaction of immune serum globulin and immune globulin intravenous with complement.

Authors:  D H Bing
Journal:  Mol Immunol       Date:  1983-08       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.